Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients (NCT04155515) | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 2019-06-13 |
| To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients (NCT03593447) | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 2018-03-15 |
| To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers (NCT03610880) | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 2017-10-17 |
Track Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.